AbbVie-Allergan deal foes try again to spur an FTC crackdown

FTC building
The FTC is currently reviewing AbbVie and Allergan's proposed $63 billion merger. (FTC)

AbbVie and Allergan's megamerger is likely in the final stages of review after the pair agreed to offload three drugs, including IL-23 hopeful brazikumab. But a cadre of union and consumer groups say that's not enough—and they're taking another stab at turning regulators against the combo.

Despite AbbVie's assurances that divesting brazikumab would help level the competitive playing field after its $63 billion megamerger with Allergan, the proposed sale would not accomplish that goal, the groups told the Federal Trade Commission (FTC) in a letter (PDF) Tuesday. 

Their rationale? Brazikumab's buyer––AstraZeneca––is ill-positioned to bring the drug to market and does not have a strong enough pipeline to actively compete with AbbVie's strong position in immunology. Moreover, AbbVie's controversial use of "rebate walls" for its products, including for psoriasis med Skyrizi, would likely put any possible competitor, brazikumab included, in a tough position to compete against the more established med. 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

In late January, AstraZeneca opted to pick up brazikumab from Allergan as part of a three-drug sell-off to help clear up antitrust concerns raised during the FTC's review of the $63 billion merger. 

RELATED: AbbVie, Allergan sell 3 drugs to win U.S. antitrust clearance—and send AZ, Nestlé into new realms

Suggested Articles

The U.K. became the first Western country to authorize a COVID vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.